Sinsin Pharmaceutical Co., Ltd (KOSDAQ:002800)
South Korea · Delayed Price · Currency is KRW 4,380.00
+10.00 (0.23%)
At close: Aug 24, 2026
Sinsin Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 66,447 | 88,899 | 82,376 | 94,664 | 84,651 | 97,850 | |
Market Cap Growth | -22.20% | 7.92% | -12.98% | 11.83% | -13.49% | -29.43% |
Enterprise Value | 102,597 | 131,411 | 122,361 | 135,899 | 130,024 | 145,574 |
Last Close Price | 4380.00 | 5860.00 | 5354.84 | 6085.51 | 5387.79 | 6171.41 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.95 | 9.57 | 16.85 | 20.23 | 19.18 | - |
PS Ratio | 0.56 | 0.78 | 0.77 | 0.92 | 0.92 | 1.32 |
PB Ratio | 0.86 | 1.19 | 1.26 | 1.53 | 1.42 | 1.79 |
P/TBV Ratio | 0.87 | 1.20 | 1.26 | 1.53 | 1.43 | 1.80 |
P/FCF Ratio | 6.57 | 12.75 | 18.56 | - | 18.59 | - |
P/OCF Ratio | 5.47 | 10.36 | 13.86 | 24.09 | 15.50 | 4220.66 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.86 | 1.16 | 1.15 | 1.33 | 1.41 | 1.97 |
EV/EBITDA Ratio | 6.12 | 8.80 | 10.97 | 13.67 | 14.16 | 62.51 |
EV/EBIT Ratio | 8.08 | 12.18 | 17.76 | 22.64 | 23.96 | - |
EV/FCF Ratio | 10.15 | 18.85 | 27.57 | - | 28.56 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.53 | 0.59 | 0.70 | 0.72 | 0.73 | 0.84 |
Debt / EBITDA Ratio | 2.44 | 2.92 | 4.09 | 4.48 | 4.73 | 19.85 |
Debt / FCF Ratio | 4.04 | 6.27 | 10.27 | - | 9.55 | - |
Net Debt / Equity Ratio | 0.47 | 0.53 | 0.69 | 0.71 | 0.69 | 0.83 |
Net Debt / EBITDA Ratio | 2.17 | 2.67 | 4.04 | 4.44 | 4.49 | 19.51 |
Net Debt / FCF Ratio | 3.61 | 5.71 | 10.15 | -40.84 | 9.06 | -17.09 |
Asset Turnover | 0.87 | 0.85 | 0.84 | 0.84 | 0.78 | 0.64 |
Inventory Turnover | 3.65 | 3.87 | 4.34 | 4.60 | 4.98 | 4.60 |
Quick Ratio | 0.66 | 0.64 | 0.56 | 0.59 | 0.71 | 0.76 |
Current Ratio | 1.01 | 0.98 | 0.87 | 0.91 | 1.06 | 1.08 |
Return on Equity (ROE) | 15.57% | 13.25% | 7.54% | 7.64% | 7.62% | -2.61% |
Return on Assets (ROA) | 5.80% | 5.05% | 3.39% | 3.06% | 2.88% | -0.72% |
Return on Invested Capital (ROIC) | 10.29% | 9.08% | 5.95% | 5.80% | 5.40% | -1.35% |
Return on Capital Employed (ROCE) | 16.00% | 14.00% | 9.80% | 8.30% | 6.90% | -1.70% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 21, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 16.78% | 10.45% | 5.93% | 4.94% | 5.21% | -1.51% |
FCF Yield | 15.22% | 7.84% | 5.39% | -1.14% | 5.38% | -2.72% |
Payout Ratio | 8.16% | 9.80% | 18.62% | 16.21% | - | - |
Buyback Yield / Dilution | 0.26% | 0.07% | -0.07% | - | - | - |
Total Shareholder Return | 1.63% | 0.07% | -0.07% | - | - | - |